BPC-157 TB-500 Blend dosage Calculator

The presets in our calculator reflect practical fixed-ratio blend amounts informed by component-level BPC-157 and thymosin beta-4/TB-500 research. No controlled study has established a standardized dosage for the finished BPC-157 + TB-500 blend.

• Low (0.5mg / 500mcg total blend): In a 1:1 formulation, this provides 0.25mg / 250mcg of BPC-157 and 0.25mg / 250mcg of TB-500. This is a conservative calculation preset that keeps the BPC-157 component near commonly discussed lower fixed amounts while modeling the TB-500 component as a smaller, more frequent exposure.
• Mid (1mg total blend): Provides 0.5mg / 500mcg of each peptide. This is the most practical midpoint for a 1:1 blend because it gives users a straightforward calculator setting without assuming that either component follows its standalone protocol.
• High (2mg total blend:) Provides 1mg of BPC-157 and 1mg of TB-500. This represents the upper general-purpose calculator preset. It should not be interpreted as a clinically validated combination dose or evidence that higher amounts produce stronger outcomes.
  

BPC-157 is commonly administered once daily in preclinical tendon, ligament, muscle, and gastrointestinal models. Full-length thymosin beta-4 research has also frequently used repeated or daily administration, although the dose and route vary substantially by model.¹²³⁴⁵

TB-500 is often discussed anecdotally in twice-weekly standalone protocols, but this schedule is not an established requirement in controlled clinical research. There is no direct evidence showing that smaller, more frequent exposure to the TB-500 component is less effective than larger, less frequent exposure.

For a fixed-ratio BPC-157 + TB-500 blend, Daily is therefore the most practical calculator default. It aligns with the BPC-157 research pattern and distributes the TB-500 portion across smaller repeated amounts. Twice-weekly, every-other-day, and custom options can remain available for alternative modeling.

The two components have been studied using several routes.

BPC-157 preclinical studies have used oral, intraperitoneal, local, topical, and other injected routes depending on the tissue model.¹²³ TB-500-specific clinical-route evidence is extremely limited, while studies of its parent peptide, thymosin beta-4, have used topical, intraperitoneal, intravenous, and localized administration.⁴⁵⁶

For a lyophilized injectable BPC-157 + TB-500 blend calculator, Subcutaneous is the most practical default route. However, this reflects the product format and common injectable research modeling—not a published clinical standard for the finished combination.

Published study duration varies according to the injury model and the component being examined.

• Acute and early-repair studies: BPC-157 and thymosin beta-4 experiments often evaluate wound closure, inflammation, cell migration, or early tissue organization over several days to approximately two weeks.¹⁴
• Tendon, ligament, and muscle studies: Longer preclinical models commonly evaluate tissue remodeling, biomechanical strength, collagen organization, and functional recovery over several weeks.²³⁵

The most important limitation is that BPC-157 + TB-500 has not been validated as a standardized combination in controlled clinical trials.

BPC-157 has shown tissue-repair effects across numerous animal and cellular models, but human evidence remains limited to small observational reports and very small pilot studies. TB-500 presents an additional evidence problem: much of the biological rationale attributed to TB-500 is extrapolated from research on full-length thymosin beta-4, while commercial TB-500 is generally identified as an acetylated LKKTETQ fragment.⁶⁷ The two should not automatically be treated as pharmacologically interchangeable.

The small intra-articular case series involving BPC-157 alone or combined with thymosin beta-4 did not include randomization, placebo control, standardized combination dosing, or sufficient sample size to establish a validated blend protocol.⁸

FDA currently states that compounded BPC-157 may present immunogenicity and peptide-impurity concerns. FDA likewise reports that TB-500 may pose immunogenicity risks and that it has not identified adequate human-exposure data to determine its safety.⁹

1. Starešinić M, Sebečić B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocyte growth. Journal of Orthopaedic Research. 2003;21(6):976–983. https://pubmed.ncbi.nlm.nih.gov/14554208/
2. Cerovečki T, Božić I, Šikić P, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. Journal of Orthopaedic Research. 2010. https://pubmed.ncbi.nlm.nih.gov/20225319/
3. Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor. 2010. https://pubmed.ncbi.nlm.nih.gov/20190676/
4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364–368. https://pubmed.ncbi.nlm.nih.gov/10469335/
5. Xu B, Yang M, Li Z, et al. Thymosin beta-4 enhances the healing of medial collateral ligament injury in rat. Regulatory Peptides. 2013;184:1–5. https://pubmed.ncbi.nlm.nih.gov/23523891/
6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421–429. https://pubmed.ncbi.nlm.nih.gov/16099219/
7. Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography–mass spectrometry. Journal of Chromatography A. 2012.
   https://pubmed.ncbi.nlm.nih.gov/23084823/
8. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
9. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
   https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks